NERV - Minerva Neurosciences, Inc.
| Previous Close | 4.23 |
| Open | 7.77 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 800 |
| Day's Range | 5.62 - 8.32 |
| 52 Week Range | 4.07 - 12.95 |
| Volume | 27,799,291 |
| Avg. Volume | 584,975 |
| Market Cap | 231.421M |
| Beta (3Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga•15 hours ago
Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial
Shares of thinly traded micro-cap biotech Minerva Neurosciences Inc (NASDAQ: NERV ) spiked higher on Monday. What Happened Minerva announced results of a Phase 2b study that evaluated its seltorexant, ...
- MarketWatch•18 hours ago
UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals
Minerva Neurosciences Inc. shares soared 34% in premarket trade Monday, after the company said its trial of Seltorexant as a treatment for insomnia met its primary and key secondary goals. The company said the Phase 2b trial of the drug met its primary endpoint of latency to persistent sleep, or LPS, at Night 1 in 10 mg and 20 mg doses of Seltorexant. It also met its key secondary endpoint, defined as wake after sleep onset over first 6 hours at Night 1. The beneficial effects were maintained over time and were consistent in adults and elderly patients. "The findings from this study demonstrate that seltorexant significantly improves sleep induction and prolongs sleep duration," said Professor Thomas Roth, Director of the Sleep Disorders and Research Center at Henry Ford Hospital. "The results also demonstrate that seltorexant showed a significantly greater improvement in these sleep parameters compared to zolpidem." The study involved 365 patients with a mean age of 57.8, ranging from 22 to 84 years of age. Minerva shares have fallen 37.2% in 2019 through Friday, while the S&P 500 has gained 17.7%.
- Benzinga•last month
Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug
The drug was evaluated in adult patients with major depressive disorder who have responded inadequately to selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NERV earnings conference call or presentation 6-May-19 12:30pm GMT
Q1 2019 Minerva Neurosciences Inc Earnings Call
- Simply Wall St.•2 months ago
Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV)
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for Minerva Neurosciences, Inc. (NASDAQ:NERV) reflect what it's really worth...
Motley Fool•2 months agoMinerva Neurosciences, Inc. (NERV) Q1 2019 Earnings Call Transcript
NERV earnings call for the period ending March 31, 2019.
- Associated Press•2 months ago
Minerva Neurosciences: 1Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 41 cents per share. Minerva Neurosciences shares have increased 12% since the beginning of the year. The stock has risen 22% in the last 12 ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT
Q4 2018 Minerva Neurosciences Inc Earnings Call
Motley Fool•3 months agoMinerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript
NERV earnings call for the period ending December 31, 2018.
- Associated Press•3 months ago
Minerva Neurosciences: 4Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 34 cents per share. For the year, the company reported that its loss widened to $50.2 million, or $1.29 per share. Minerva Neurosciences shares ...
- Simply Wall St.•6 months ago
How Much Of Minerva Neurosciences, Inc. (NASDAQ:NERV) Do Institutions Own?
Every investor in Minerva Neurosciences, Inc. (NASDAQ:NERV) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
- Zacks•7 months ago
Minerva Neurosciences Sees Hammer Chart Pattern: Time to Buy?
Minerva Neurosciences has been struggling lately, but the selling pressure may be coming to an end soon.
- Thomson Reuters StreetEvents•8 months ago
Edited Transcript of NERV earnings conference call or presentation 5-Nov-18 1:30pm GMT
Q3 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•8 months ago
Minerva Neurosciences: 3Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 31 cents. Minerva Neurosciences shares have risen 93 percent since the beginning of the year. The stock has increased ...
- Simply Wall St.•8 months ago
Minerva Neurosciences Inc (NASDAQ:NERV): Risks You Need To Consider Before Buying
If you own shares in Minerva Neurosciences Inc (NASDAQ:NERV) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- Zacks•10 months ago
J&J Submits NDA to the FDA for Depression Drug in Adults
Johnson & Johnson (JNJ) submits NDA to the FDA for esketamine nasal spray seeking approval for treatment-resistant depression in adults in the United States.
- Benzinga•10 months ago
The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 22) Acer Therapeutics Inc (NASDAQ: ACER ) Avanos Medical Inc (NYSE: ...
- Thomson Reuters StreetEvents•11 months ago
Edited Transcript of NERV earnings conference call or presentation 2-Aug-18 12:30pm GMT
Q2 2018 Minerva Neurosciences Inc Earnings Call
- Associated Press•11 months ago
Minerva Neurosciences: 2Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 32 cents per share. Minerva Neurosciences shares have climbed 32 percent since the beginning of the year. The stock has increased 13 percent ...
